Our group focuses on translational research activities aimed at developing cost-effective vaccines, diagnostic kits and protein therapeutics using recombinant protein technology. For this we capitalize on our proficiency in production of recombinant proteins using different protein expression platforms such as prokaryotic (Lactococcus lactis and Escherchia coli), eukaryotic (Pichia pastoris, Kluyveromyces lactis, and Bombyx mori, a higher eukaryote platform for bulk production of glycosylated proteins). Two of the major research programs (funded by BIRAC-NBM, Department of Biotechnology and ICMR) undertaken by our group involves developing novel recombinant chimeric malaria vaccines ( P. falciparum and P. vivax) targeting the pre-erythrocytic development in man and preventing community transmission through blocking the parasite development in the mosquito vector.Other ongoing research interests of our group involve developing novel vaccines and diagnostics kits against Filariasis, Dengue, Japanese Encephalitis Virus, and other infectious agents or non-infectious diseases, as per institutional mandate.

Our group focuses on translational research activities aimed at developing cost-effective vaccines, diagnostic kits and protein therapeutics using recombinant protein technology. For this we capitalize on our proficiency in production of recombinant proteins using different protein expression platforms such as prokaryotic (Lactococcus lactis and Escherchia coli), eukaryotic (Pichia pastoris, Kluyveromyces lactis, and Bombyx mori, a higher eukaryote platform for bulk production of glycosylated proteins). One of the major research program (funded by BIRAC-NBM, Department of Biotechnology) undertaken by our group involves developing novel recombinant chimeric malaria vaccines targeting the pre-erythrocytic development in man and preventing community transmission through blocking the parasite development in the mosquito vector. Additionally, our group aims to develop a novel Virus-Like Particle (VLP) based platform for conjugation with antigens of choice to improve their immunogenicity (Dr. Susheel Singh’s approved DHR-NRI Fellowship project).Other ongoing research interests of our group involve developing novel vaccines and diagnostics kits against Plasmodium vivax, Filariasis, Dengue, Japanese Encephalitis Virus, and other infectious agents or non-infectious diseases, as per institutional mandate.

Development of multi-stage (asexual and sexual) malaria vaccine candidate

-Development of functional in vitro assay for vaccine clinical trial.-Malaria vaccine.-Parasitic genotyping and making antigens for immunization and serological studies.-Human pappiloma virus; VLP technology using as a drug delivery system.-Malaria parasite antigen discovery using proteomic tools.

-Development of functional in vitro assay for vaccine clinical trial.-Development of multi-stage (asexual and sexual) malaria vaccine candidate.-Malaria parasite antigen discovery using proteomic tools.

Malaria Parasite Cell Biology, Cloning and production of CDKs and CS protein and Antimalarial drug discovery

Strategy planning and experiment design for cloning, expression and purification of recombinant proteins in Ecoli, Pichia pastoris and animal cell line in R&D scale.

Research on bacteria and archea under the taxonomic capacity building